BMC Cancer: Comparison of survival outcomes after radical chemoradiotherapy in patients with cervical squamous cell carcinoma (SCC) and adenocarcinoma/adenosquamous carcinoma (AC/ASC)

Recently, a team from the Southern Hospital of Southern Medical University published a study in the journal BMC Cancer, mainly comparing the outcomes of patients with cervical squamous cell carcinoma (SCC) and adenocarcinoma/adenosquamous carcinoma (AC/ASC) after radiotherapy and chemotherapy.
survival outcome
.

To compare the survival outcomes of patients with cervical squamous cell carcinoma (SCC) and adenocarcinoma/adenosquamous carcinoma (AC/ASC) after chemoradiotherapy
.

The overall survival (OS) and disease-free survival (DFS) of Chinese cervical cancer SCC and AC/ASC patients were compared using propensity score matching (1:4)
.

According to this criterion, 5466 patients were included, including 5251 and 215 patients in the SCC and AC/ASC groups, respectively
.

After propensity score matching (1:4), there were 843 and 212 cases in the two groups, respectively

In the overall population, before propensity score matching, the 5-year OS rates in the SCC and AC/ASC groups were 73.
0% and 57.
4%, respectively (p<0.
001), and the DFS rates were 68.
0% and 48.
1% (p<0.
001)
.

Cox multivariate analysis showed that the AC/ASC group had a higher risk of death or recurrence/mortality (HR=1.

In the overall population, before propensity score matching, the 5-year OS rates in the SCC and AC/ASC groups were 73.

In stage I-IIA2 patients, before propensity score matching, the 5-year OS rates were 76.
1% vs 70.
5% in the SCC and AC/ASC groups, respectively (p<0.
01), and the DFS rates were 72.
8% and 56.
8%, respectively (P=0.
015) )
.

Cox multivariate analysis showed that there was no significant difference in the risk of death between the two groups, but the AC/ASC group had a higher risk of recurrence/death

In stage I-IIA2 patients, before propensity score matching, the 5-year OS rates were 76.

Among stage IIB-IV patients, before propensity score matching, the 5-year OS rates were 72.
5% and 67.
1% in the SCC and AC/ASC groups, respectively (P<0.
001), and the DFS rates were 67.
1% and 46.
1%, respectively (P<0.
001).
)
.

Cox multivariate analysis showed that the AC/ASC group had a higher risk of death or recurrence/mortality (HR=2.

Among stage IIB-IV patients, before propensity score matching, the 5-year OS rates were 72.

Taken together, the study showed that for stage I-IIA2, there was no significant difference in 5-year survival between SCC and AC/ASC groups, but AC/ASC patients were more likely to relapse
.

In advanced stage IIB-IV, the prognosis of AC/ASC group after radical chemoradiotherapy was worse than that of SCC

The study showed that for stage I-IIA2, there was no significant difference in 5-year survival between the SCC and AC/ASC groups, but AC/ASC patients were more likely to relapse

Original source:

Original source:

Liu P, Ji M, Kong Y, Huo Z, Lv Q, Xie Q, Wang D, Chen B, Wang H, Cui Z, Wang Q, Bin X, Lang J, Chen C.

Liu P, Ji M, Kong Y, Huo Z, Lv Q, Xie Q, Wang D, Chen B, Wang H, Cui Z, Wang Q, Bin X, Lang J, Chen C.
Comparison of survival outcomes between squamous cell carcinoma and adenocarcinoma/adenosquamous carcinoma of the cervix after radical radiotherapy and chemotherapy.
BMC Cancer.
2022 Mar 25;22(1):326.
doi: 10.
1186/s12885-022-09401-x.
PMID: 35337279; PMCID: PMC8957141.
Herein message